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Objectives:  The aim of our work was to report on the clinical outcome of a moderately 
hyprofractionated radiotherapy regimen in elderly patients affected by head and neck 
squamous cell carcinoma (HNSCC).   
Material and methods: HNSCC aged > 65 deemed unsuitable for curatively-intended 
concurrent chemo-radiotherapy or high-dose radiotherapy by clinical judgement were 
further evaluated with the Geriatric 8 (G8) questionnaire and Charlson comorbidity index 
(CCI). In case of a G8 score < 14, a de-intensified radiation schedule of 40 Gy delivered in 
16 fractions was prescribed.  
Results: Thirty-six patients were treated between 2011 and 2016. The median age of the 
cohort was 77.5 (range: 65-91 years) with a combined ECOG PS of 2-3 in 77.8% and CCI 
of > 8 in 25% patients, respectively. At a median follow-up of 13 months (range 2 – 62 
months), the 6-month and 1-year rates of loco-regional control and progression-free 
survival were 42%, 28% and 36% and 20%, respectively. At univariate analysis, log-rank 
test showed that age > 75 years (p=0.036), worse PS (ECOG > 2; p=0.027), lower G8 
score (<9; p=0.027) and PTV volume greater than 200 cc (p= 0.038) had a significant 
correlation with PFS. The negative impact of the PTV volume on PFS was the only 
parameter confirmed in the multivariate analysis (HR 2.68; 95% CI: 1.24-5.81, p=0.013). 
No grade 4-5 toxicity was observed, while 13/36 patients (36%) had G3 acute side effects.  
Conclusion: the hypofractionated radiation schedule evaluated provides clinical benefit 




















Introduction   
 
Head and neck squamous cell carcinoma (HNSCC) represents the sixth most common 
malignant tumor worldwide, with over 600.000 new cases diagnosed per year [1]. In last 
15 years, human papilloma virus (HPV) infection has been recognized to account for a 
distinct epidemiologic trend occurring mainly in western countries, leading to a rising 
incidence of oropharyngeal cancer (OPC) particularly in male patients in their 5th decade 
of life [2,3]. Next to the pathogenesis of HPV-driven OPC [4], the development of HNSCC 
is still largely the result of a chronic exposure to tobacco and alcohol – induced field 
cancerization [5] of the upper aerodigestive mucosal tract. As a consequence, almost half 
of the patients are older than 65 years at diagnosis [6]. In next 20 years, the incidence of 
HNSCC is expected to increase by 64% in the elderly population [7]. Level 1 evidence [8, 
9, 10] supports the use of multimodality treatment for the loco-regionally advanced disease 
which can be found in over 60% of cases: however, none of the intensified approaches 
addressed in clinical trials and metanalyses have demonstrated to provide clinical benefit 
in patients older than 65 years. Moreover, compared with younger subjects, elderly 
patients with head and neck cancer are more frequently burdened with treatment-induced 
severe acute toxicity [11, 12], multiple comorbidities [13] and non-cancer related death 
[14]. The aim of our work was to evaluate the feasibility and clinical benefit of a de-
intensified hypofractionated radiotherapy in elderly patients deemed unfit for standard 
curative treatment, a group for whom at present no specific evidence-based 
recommendations [15, 16] are available.  
 




Following the definition of the National Institutes of Health [17], patients with age > 65 
years were defined as old. In case of locally advanced HNSCC for whom the 
multidisciplinary team recommended a curatively-intended non surgical treatment, a 
prospective evaluation of frailty was performed when the treating oncologist considered 
the elderly patient unfit for standard therapy by clinical judgement. First, the Geriatric 8 
(G8) screening tool was administered in order to identify subjects potentially able to 
undergo an intensive therapy. By definition, a G8 score > 14 was taken as a cutoff value 
for healthy patients suitable for standard treatment [18]. In case of a lower score, the 
individual burden of comorbidities was further investigated through the Charlson 
comorbidity index (CCI) [19]. Both tests were therefore used to support the clinical 
decision towards a de-intensified therapeutic approach. Patients affected by histologically 
proven, squamous cell carcinoma of any sub-site of the head and neck with an ECOG 
performance status of 1-3 could be included in our observational prospective study. Study 
design and study procedures were reviewed and approved by institutional ethics 





All patients underwent staging workup including computed tomography (CT) with contrast 
medium of the head and neck and chest or magnetic resonance (MR) of the head and 
neck with contrast medium combined with chest CT to rule out the presence of distant 
metastases. Positron emission tomography (PET) with 18F – fluorodeoxyglucose was 
performed in selected cases. A CT scan (Light Speed 16; GE Healthcare Medical 
Systems, Milwaukee,WI, USA) was acquired at 3 mm slice width for radiation treatment 
planning. A personalized thermoplastic face mask was created for all patients. The gross 
tumor volume (GTV) consisted of the primary tumor and pathologic lymph nodes. A single 
clinical target volume (CTV) was made up by the GTVs plus a 1 cm margin. The first 
macroscopically unaffected lymphatic echelon was also included in the CTV. To take into 
account potential systematic and random errors, a 5 mm CTV to planning target volume 
(PTV) margin was chosen. A total dose of 40 Gy was delivered in 16 fractions of 2.5 Gy 
each. Radiotherapy was delivered by a linear accelerator (Elekta Synergy, Elekta, 
Crawley, UK) with a 3D-conformal technique or intensity modulated radiotherapy (IMRT). 
For the latter, a volumetric modulated arc therapy (VMAT) solution was chosen. All VMAT 
plans were calculated with Monaco software (Elekta, Crawley, UK). In selected cases with 
marginal or out-of-field recurrences, a second round of treatment with the same total dose 
and accelerated regimen (40 Gy/2.5 Gy fraction) was prescribed by the treating radiation 
oncologist, provided that a disease-free interval of at least 6 months was obtained and in 
accordance with cumulative dose constraints.  
 
 
Outcome measures and statistical methods 
 
A clinical evaluation at 25 days after treatment was scheduled for all patients to assess the 
resolution of radiation-induced side effects. Acute toxicity was scored according to CTCAE 
v. 4 [20]. Response assessment was performed at 2 months after treatment and every 3 
months thereafter for the first 2 years, then every 6 months. Tumor response was 
evaluated according to Recist criteria [21]. A complete response (CR) was defined as no 
visible gross tumor, partial response (PR) as at least a 30% decrease, progressive disease 
(PD) as at least a 20% increase, and stable disease (SD) as neither sufficient shrinkage to 
qualify for PR nor sufficient increase to qualify for PD. The primary outcome measure of 
the study was progression-free survival (PFS). PFS was defined as the time from the last 
day of radiotherapy to the date of the first of the following events: 
- the first day when the RECIST criteria for PD were met 
- salvage surgery or elective neck dissection performed after 15 weeks from the last 
day of treatment performed on the clinical or radiological evidence of progression;  
- death for any cause 
A pattern of failure analysis after de-intensifed RT was performed. Locoregional control 
(LRC) was defined as the time from the last day of radiotherapy to local and/or regional 
disease progression. Overall survival (OS) was defined as the time from the last day of 
treatment to death from any cause.  
Median LRC, PFS and OS were calculated. The relative estimates of LRC, PFS and OS at 
6 and 12 months were estimated by the Kaplan-Meyer method, with corresponding 95% 
confidence intervals. The predictive impact of pretreatment variables was assessed with a 
log-rank test. The risk of disease progression and death was assessed through Cox 
regression model (both univariate and multivariate analyses) calculating the hazard ratio 
(HR) with corresponding 95% confidence intervals and p values.  Baseline demographics, 






Between December 2011 and July 2016, 36 patients received the described 
hypofractionated de-intensified RT schedule. Patients’ characteristics are summarized in 
table 1. The median age of the cohort was 77.5 (range: 65-91 years), with a high 
prevalence of male subjects. Notably, the  most involved subsite of primary tumor was the 
oral cavity with a prevalence of 50% (n = 18). In most cases, patients had advanced 
tumors with stage IVA and IVB disease (86.1%). Only five patients (13.9%) had stage ≤ III 
disease. None of 6 OPC had a HPV positive disease, therefore the global cohort was HPV 
negative. Only a minority of patients (6/36; 16%) had a percutaneous endoscopic 
gastrostomy (PEG) in place before RT start. According to the G8 questionnaire, all 
patients were considered vulnerable with an individual score below 14. The unsuitability of 
our cohort for intensive treatment was further highlighted by the frail general conditions 
and high comorbidity burden (combined ECOG PS of 2-3 in 77.8% and CCI of > 8 in 25% 
of cases, respectively). A standard 3D conformal parallel or multiple field technique was 
used in 25/36 patients (69.4%) whereas VMAT was preferentially delivered from October 
2014 on (11/36, 30.6%). RT was completed as scheduled in the majority of cases (33/36, 
91.6%). In 3 patients the therapy was stopped prematurely (at 20 Gy in two cases and at 
32.5 Gy in one case, respectively) due to worsening general conditions. The median 
length of treatment interruption was  1,02 day (range 0 to 10), with no need for RT breaks 
in 30/36 (83.3%) patients. As expected, the irradiated disease burden was rather 
heterogeneous in our cohort, with a median PTV volume of 191.4 cc (range: 31.87 – 608 
cc).  As reported in Table 2, no grade 4-5 acute side effects were observed, instead the 
incidence of grade 3 side effects was 36% (13/36 patients). The most common treatment-
related toxicities were grade 1 oral mucositis and grade 1 dysphagia, both with an 
incidence of 36.1%. Early response assessment at 2 months after treatment was available 
for 33 of 36 patients (91.6%). An objective response rate of 66.6% was obtained, resulting 
from 4 complete responses (12.1%) and 18 partial responses (54.5%), respectively.  
At a median follow-up of 13 months (range 2 – 62 months), the median loco-regional 
control was 5 months. The 6-month and 1-year rates of LRC were 42% and 28%, 
respectively. Regarding PFS, all but 3 cases developed a loco-regional recurrence as first 
event of treatment failure. Overall, the median PFS was 4 months, with 6-month and 1-
year rates of 36% and 20%, respectively (figure 1). At univariate analysis, log-rank test 
showed that age > 75 years (p=0.036), worse PS (ECOG > 2; p=0.027), lower G8 score 
(<9; p=0.027) and PTV volume greater than 200 cc (p= 0.038) had a significant correlation 
with PFS. The negative impact of the PTV volume on PFS was the only parameter 
confirmed in the multivariate analysis (HR 2.68; 95% CI: 1.24-5.81, p=0.013; figure 2). 
In 6/36 cases (16.6%), a second round of treatment was prescribed at a median disease-
free interval from the end of first RT course of 6 months (range: 6-16).  
The median OS of the whole cohort was of 12 months, with resulting 6-month and 1-year 
rates of 58% and 50%, respectively (figure 3). At time of analysis, 6 patients (16%) are 





Multimodal treatment is standard of care in the curative setting of HNSCC on the basis of 
level 1 evidence. However, patients’ age is a factor that needs to be carefully taken into 
account.  
The individual patient data MACH-NC meta-analysis [8] showed that the concurrent 
addition of cisplatin-based chemotherapy to radiotherapy yielded a 6.5% improvement in 
5-year OS (hazard ratio of death, 0.81; p <0.0001). At subgroup analysis, the benefit was 
shown to be diluted with increasing age (test for trend, p=0.003). In particular, no survival 
advantage could be observed for the patients aged 71 or more, which were also markedly 
underrepresented (8% out of total 17.346 subjects included from 93 trials).  The individual 
patient data MARCH meta-analysis [9] demonstrated that altered fractionation was 
beneficial compared with conventional RT, with a 3.4% improvement in 5-year OS (HR of 
0.92, p=0.003). Of note, hyperfractionation was shown to be the most effective option, with 
a 8% gain in survival. Again, the reported benefit was attenuated by increasing age, 
disappearing for patients older than 70 years (HR of 1.08; test for trend, p =0.007), which 
were about 14% out of total 6515 subjects included. Similarly, only 45/211 (21%) of the 
patients treated with cetuximab and radiotherapy in the experimental arm of the IMCL 
9815 phase 3 trial [10] were older than 65 years, receiving no significant advantage from 
the combined treatment compared with RT alone at subgroup analysis.  
Taking altogether, these data provide indirect evidence of a lack of benefit of standard 
intensified approaches in the treatment of elderly HNSCC patients. This assumption may 
be corroborated by further observations. First, the accrual of subjects with more than 65 
years was historically very low in pivotal randomized phase 3 trials, thus hampering the 
generalizability of any incremental gain in this category. Second, the physiological loss of 
functional reserve [22] associated with aging may translate into severe toxicity [11] and 
suboptimal compliance to intensive treatment compared with younger adults, leading to a 
detrimental reduction in relative dose intensity of both radiation and systemic agents. 
Third, any potential improvement in survival may be blunted by the competing risk of non-
cancer related death due to aging itself [23]. Whereas chronological age per se should not 
be viewed as a limiting factor towards the implementation of standard of care [24, 25], it is 
the individual burden of comorbidites to play a major role in the treatment decision-making 
of HNSCC. A meta-analysis on 22.932 patients showed that the presence of comorbidity 
was significantly correlated with worse overall survival (HR of 1.38; 95% CI: 1.32–1.43) 
[13]. Since chronic exposure to tobacco and/or alcohol is the main etiopathogenetic factor 
implied in the development of HNSCC, it is recognized that a substantial proportion [26] of 
elderly HNSCC patients are vulnerable to a variable extent due to mainly concurrent 
cardiovascular, pulmonary and liver diseases. In recent years, a geriatric assessment 
intervention has been advocated to support cancer individualized treatment decision 
making in the elderly population [27, 28]. In order to single out subjects fit enought to be 
potentially amenable to receive intensive standard treatment, different screening tools 
have been proposed [29]. Among them, the G8 questionnaire was shown to be the most 
accurate in identifying the patients at highest risk of frailty. In particular, a systematic 
review of the literature [29]  and a prospective non-interventional study [30] on 937 
patients with cancer aged 70 or more showed that its sensitivity in detecting unfit elderly 
was of 87% and 86.5%, respectively. A pilot study [31] performed on 35 HNSCC patients 
aged 65 years or older confirmed that a G8-based screening assessment was able to 
discriminate vulnerable subjects more accurately than the MDT evaluation alone (detection 
increased from 20% to 40%; p=0.12).  
Overall, no curatively-intended recommendation is specifically available for locally 
advanced HNSCC in elderly patients deemed unfit to receive standard treatment.  
The use of de-intensifed radiation regimens has been mainly described in the context of 
clinical scenarios with clear palliative intent. Hypofractionated schedules such as 20 Gy in 
5 consecutive fractions [32], 30 Gy in 5 fractions delivered over 3 weeks [33] and 14 Gy in 
4 fractions given twice daily in 2 consecutive days [34, 35] were shown to be effective in 
yielding symptomatic relief and improved quality of life with minimal toxicity. The adoption 
of more protracted, moderately hypofractionated treatments was reported in few single 
center experiences when a prolonged locoregional control was pursued on top of a pure 
palliative purpose.  
Over an 11-year time span, Al-Mamgani et al [36] treated 158 patients with the “Christie 
regimen” consisting of 50 Gy given in 16 fractions of 3.125 Gy. A standard 3D-conformal 
technique was used to enclose the macroscopic primary and nodal disease plus a 1 cm 
margin. A 73% ORR was obtained despite the occurrence of non-negligible acute toxicity 
(grade > 3 dermatitis and mucositis of 45% and 65%, respectively). At a median follow-up 
of 16.4 months, the 1- and 3-year locoregional control rates were 62% and 32%, 
respectively. Between 2000 and 2005, Agarwal et al [37] treated 110 unresectable 
HNSCCs with a telecobalt machine delivering 40 Gy in 16 fractions, with possible 
escalation to 50 Gy in selected cases. Complete and partial responses were showed in 11 
(10%) and 69 (63%) patients, respectively, with a resulting 73% ORR. At a median follow-
up of 6 months, a 1-year PFS of 55.1% (95% CI: 40.3%–69.9%) was achieved. More 
recently, Bledsoe et al [38] reported on a split-course regimen consisting of two rounds of 
30/36 Gy given at 3 Gy/fraction with a 3 to 5 weeks break between them. Between 2002 
and 2010, 65 patients with advanced age, severe comorbidities, anticipated intolerance to 
standard treatment or oligometastatic disease received either a conventional 3-field 
approach or IMRT. Both courses were completed in 89% of cases. Excluding 26 
recurrent/metastatic patients from the cohort, a 91% ORR was obtained at 3 months after 
treatment in 29/39 subjects (50% CR and 41% PR), with resulting median LRC and OS of 
25.7 and 8.9 months, respectively.  Notably, the median age of the cohort was 71 (range 
42-101 years). An IMRT-simultaneous integrated boost (SIB) technique was used by 
Straube et al [39] in 27 patients for whom the multidisciplinary team prescribed a reduced-
volume RT, mainly due to age, comorbidity burden or metastatic disease (9/27 had stage 
IVC). Out of 19 patients evaluable for response, an early 6-week ORR of 52.6% was 
achieved (1 and 9 patients achieved CR and PR, respectively).  
Taking all data together, these moderately hypofractionated regimens are characterized by 
mid-term efficacy in securing loco-regional control with acceptable toxicity. However, the 
interpretation of the aforementioned studies is hampered by their significant heterogeneity 
in terms of patients’ selection, to certain extent biased by the inclusion of 
recurrent/metastatic patients, elegibility to concurrent chemotherapy for some patients and 
variable symptomatic burden.  
The results of our study are consistent with previous experiences in terms of early and 
mid-term efficacy. We also showed that a de-intensified, moderately hypofractionated 
regimen of 40 Gy in 16 fractions of 2.5 Gy each is an effective approach providing rapid 
disease regression (2-month ORR of 66.6%) with low toxicity and potential for sustained 
locoregional control in selected patients. When dealing with locally advanced HNSCC in 
the elderly, proper patients’ selection is a crucial step in treatment decision-making [40]. 
To our knowledge, our single-center experience is the fist to report on the support of a 
geriatric screening tool such as the G8 questionnaire towards the adoption of a de-
intensified radiation schedule in frail elderly patients. Compared with previous experiences, 
the poor long-term outcome data in our cohort may reflect the inclusion of patients with 
homogeneous, unfavorable features such as the low G8 score, high CCI, prevalent ECOG 
PS of 2 and the age cutoff of 65 years. In addition, the exclusion of patients with 
recurrent/metastatic disease from our cohort may be seen as another strenght towards an 
unbiased interpretation of the possible anticancer efficacy of a low dose hypofractionated 
regimen as ours. According to our analysis, a large disease volume in an elderly and frail 
patient is a factor associated with dismal prognosis.  In particular, we can hypothesize that 
above 200 cc PTV volume a shorter hypofractionated regimen may be better suited in light 
of the limited life expectancy. Several limitations have to be taken into account in 
interpreting our data. First, a comprehensive geriatric assessment (CGA) was not 
performed due to logistic reasons. However, although cumbersome and time-consuming, 
the CGA is considered the gold standard instrument to tailor cancer treatment intensity in 
elderly patients [41]. We used the G8 questionnaire as a quick screening assessment that 
could aid the therapeutic decision together with the clinical evaluation and Charlson 
comorbidity score. Moreover, quality of life was not formally evaluated in our study. 
Potentially, this could have allowed us to highlight the benefit of a de-intensifed approach 
in a frail patients’ population, further reinforcing the value of our strategy. Indirectly, the 
rate of early disease control and low toxicity might support our treatment in preventing 
rapid QoL deterioration due to disease progression. The small sample size of the cohort 
limits the generalizability of our findings. In the future, the results of the ongoing 
randomized ELAN phase 3 trial [42] testing the non-inferiority of hypofractionated split-
course versus standard RT will provide valuable insight on this topic.  
 
Conclusions 
A de-intensified, moderately hypofractionated radiation schedule provides clinical benefit 
with low toxicity in frail, elderly patients affected by locally advanced HNSCC. In this 
setting, a PTV larger than 200 cc is an unfavorable prognosticator of response. The 
treatment of non-metastatic HNSCC patients unfit for intensive standard therapy remains a 
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TABLE 1. Patients’ characteristics. 
Characteristic No. of patients (%), n = 36 
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                       32 (89%) 
  


























Abbreviations: ECOG, Eastern Cooperative Oncology Group; CCI, Charlson 





TABLE 2. Acute treatment-related toxicity according to CTCAE version 4.03. 
 No. (%) by toxicity grade  












13 (36.1%) 8 (22.2%) 6 (16.7%) 
Radiation dermatitis  
 
10 (27,8%) 10 (27.8%) 0 













Figure. 2 Impact of PTV volume on PFS 
 
 





Figure. 3  Overall survival for the entire population 
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